Press Releases Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Real-time Estimate Cboe BZX Other stock markets 10:24:35 07/05/2024 pm IST			5-day change	1st Jan Change
411.3 ^USD	+2.19%		+4.64%	+1.02%

02:12pm	FOMO is Back
01:53pm	ANALYST RECOMMENDATIONS : Nvidia, The Home Depot, Lowe's, Rollins...

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vertex: Q1 Earnings Snapshot	07/05	AQ
Vertex Reports First Quarter 2024 Financial Results	07/05	BU
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older	26/04	BU
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES	23/04	PR
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES	23/04	AQ
Vertex Announces Advancements of Suzetrigine in Acute and Neuropathic Pain	19/04	AQ
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain	18/04	BU
Vertex Pharma scientist talks about the long road to developing non-addictive painkillers	16/04	AQ
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences	11/04	BU
Vertex to Announce First Quarter 2024 Financial Results on May 6	10/04	BU
Vertex Advances Inaxaplin into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease	02/04	AQ
Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia	01/04	AQ
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease	01/04	BU
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey	28/03	AQ
InvestorBrandMedia: FDA Approves Vertex Pharmaceuticals (NASDAQ:VRTX) VX-407 for Phase I Study in Groundbreaking Move Against Polycystic Kidney Disease"	25/03	AQ
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	22/03	AQ
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	21/03	BU
Vertex Pharmaceuticals Incorporated : ID&E Fact Sheet	05/03	PU
Vertex Receives CHMP Positive Opinion for KALYDECO for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older	26/02	AQ
Vertex Receives CHMP Positive Opinion for KALYDECO® for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older	23/02	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Vertex Pharmaceuticals Incorporated : Vertex and Crispr to market $2.2 million treatment for sickle cell disease

December 11, 2023 at 04:17 pm IST